Levi & Korsinsky notifies investors that it has commenced an investigation into Ventyx Biosciences, Inc. (NASDAQ: VTYX) concerning potential violations of the federal securities laws.
Ventyx issued a press release on December 2, 2025, "providing an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent pericarditis (‘RP')." In relevant part, the Company's Chief Executive Officer said that "[w]e are . . . revising our guidance for topline data release from the interim analysis of the Phase 2 RP trial to Q1 2026," describing the shift as "providing us with an opportunity to introduce dose-ranging studies with our new once-daily or QD formulation in the current Phase 2 study while also expanding into Canada, EU and the UK, a strategy we feel will accelerate Phase 3 timelines." Following this news, Ventyx's stock price fell over 15% on December 2, 2025.
If you suffered a loss on your Ventyx Biosciences, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





